Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase 2 Completed
97 enrolled 35 charts
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Phase 2 Completed
30 enrolled 8 charts
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Phase 1 Completed
31 enrolled
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Phase 1/2 Completed
52 enrolled 17 charts
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Lobradimil and Carboplatin in Treating Children With Brain Tumors
Phase 2 Completed
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
Phase 2 Completed
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
Phase 1 Completed
36 enrolled
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
95 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Docetaxel in Treating Children With Recurrent Solid Tumors
Phase 2 Completed
20 enrolled
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase 1 Completed
36 enrolled
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 2 Completed
200 enrolled
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
Phase 2 Completed
40 enrolled
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled